Clinical Trial: A First Time In Human Study To Assess The Compound GSK615915
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: A Randomised, Single and Repeat Dose, Double-blind, Placebo Controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of GSK615915 in Healthy Volunteers and Mild Asthmatics.
Brief Summary: GSK615915A is being developed as a novel surfactant for use in the formulation of GSK's future generation of Metered Dose Inhalers (MDIs). A surfactant in a MDI would provide a more stable drug suspension, this in turn will produce a consistent dose of drug being delivered with each puff.
Detailed Summary:
Sponsor: GlaxoSmithKline
Current Primary Outcome: Side effects Lung function Blood tests Heart rate and blood pressure Heart monitored (ECG)
Original Primary Outcome: Same as current
Current Secondary Outcome: Levels of GSK615915A and any breakdown products in the blood and urine.
Original Secondary Outcome: Same as current
Information By: GlaxoSmithKline
Dates:
Date Received: November 15, 2006
Date Started: November 2005
Date Completion:
Last Updated: May 31, 2012
Last Verified: February 2011